The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease
Open accessAbstract
Antibody therapies to prevent or limit filovirus infections have received modest interest in recent years, in part because of early negative experimental evidence. We have overcome the limitations of this approach, leveraging the use of antibody from nonhuman primates (NHPs) that survived challenge to filoviruses under controlled conditions. By using concentrated, polyclonal IgG antibody from these survivors, we treated filovirus-infected NHPs with multiple doses administered over the clinical phase of disease. In the first study, Marburg virus (MARV)-infected NHPs were treated 15 to 30 min postexposure with virus-specific IgG, with additional treatments on days 4 and 8 postexposure. The postexposure IgG treatment was completely protective, with no signs of disease or detectable viremia. MARV-specific IgM antibody responses were generated, and all macaques survived rechallenge with MARV, suggesting that they generated an immune response to virus replication. In the next set of studies, NHPs were infected with MARV or Ebola virus (EBOV), and treatments were delayed 48 h, with additional treatments on days 4 and 8 postexposure. The delayed treatments protected both MARV- and EBOV-challenged NHPs. In both studies, two of the three IgG-treated NHPs had no clinical signs of illness, with the third NHP developing mild and delayed signs of disease followed by full recovery. These studies clearly demonstrate that postexposure antibody treatments can protect NHPs and open avenues for filovirus therapies for human use using established Food and Drug Administration-approved polyclonal or monoclonal antibody technologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunotherapy: past, present and future
Waldmann, T. A. (2003) · Nature Medicine · doi:10.1038/nm0303-269 · Cited by 628
Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team.
(1978) · Europe PMC (PubMed Central) · Cited by 616
Pathogenesis of Ebola Hemorrhagic Fever in Cynomolgus Macaques
Geisbert, T. W., Hensley, L. E., Larsen, T., Young, H. A., Reed, D. S., Geisbert, J. B., Scott, D. P., Kagan, E., Jahrling, P. B., & Davis, K. J. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63591-2 · Cited by 576
Geisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B., Honko, A. N., Sood, V., Johnson, J. C., de Jong, S., Tavakoli, I., Judge, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60357-1 · Cited by 463
Epitopes Involved in Antibody-Mediated Protection from Ebola Virus
Wilson, J. A., Hevey, M., Bakken, R., Guest, S., Bray, M., Schmaljohn, A. L., & Hart, M. K. (2000) · Science · doi:10.1126/science.287.5458.1664 · Cited by 459
Treatment of Ebola Hemorrhagic Fever with Blood Transfusions from Convalescent Patients
Mupapa, K., Massamba, M., Kibadi, K., Kuvula, K., Bwaka, A., Kipasa, M., Colebunders, R., Muyembe‐Tamfum, J. J., & the International Scientific and Technical Committee (1999) · The Journal of Infectious Diseases · doi:10.1086/514298 · Cited by 420
Geisbert, T. W., Hensley, L. E., Jahrling, P. B., Larsen, T., Geisbert, J. B., Paragas, J., Young, H. A., Fredeking, T. M., Rote, W. E., & Vlasuk, G. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15012-x · Cited by 382
Ebola Virus Can Be Effectively Neutralized by Antibody Produced in Natural Human Infection
Maruyama, T., Rodriguez, L. L., Jahrling, P. B., Sanchez, A., Khan, A. S., Nichol, S. T., Peters, C. J., Parren, P. W. H. I., & Burton, D. R. (1999) · Journal of Virology · doi:10.1128/jvi.73.7.6024-6030.1999 · Cited by 293
Effective Post-Exposure Treatment of Ebola Infection
Feldmann, H., Jones, S. M., Daddario-DiCaprio, K. M., Geisbert, J. B., Ströher, U., Grolla, A., Bray, M., Fritz, E. A., Fernando, L., Feldmann, F., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030002 · Cited by 288
Jahrling, P. B., Geisbert, T. W., Geisbert, J. B., Swearengen, J. R., Bray, M., Jaax, N. K., Huggins, J. W., LeDuc, J. W., & Peters, C. J. (1999) · The Journal of Infectious Diseases · doi:10.1086/514310 · Cited by 269
Neutralizing Antibody Fails to Impact the Course of Ebola Virus Infection in Monkeys
Oswald, W. B., Geisbert, T. W., Davis, K. J., Geisbert, J. B., Sullivan, N. J., Jahrling, P. B., Parren, P. W. H. I., & Burton, D. R. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030009 · Cited by 230
Parren, P. W. H. I., Geisbert, T. W., Maruyama, T., Jahrling, P. B., & Burton, D. R. (2002) · Journal of Virology · doi:10.1128/jvi.76.12.6408-6412.2002 · Cited by 204
Advanced antisense therapies for postexposure protection against lethal filovirus infections
Warren, T. K., Warfield, K. L., Wells, J., Swenson, D. L., Donner, K. S., Van Tongeren, S. A., Garza, N. L., Dong, L., Mourich, D. V., Crumley, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2202 · Cited by 203
Enria, D., Fernandez, N., Briggiler, A., Levis, S., & Maiztegui, J. (1984) · The Lancet · doi:10.1016/s0140-6736(84)90299-x · Cited by 184
Daddario-DiCaprio, K. M., Geisbert, T. W., Ströher, U., Geisbert, J. B., Grolla, A., Fritz, E. A., Fernando, L., Kagan, E., Jahrling, P. B., Hensley, L. E., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68546-2 · Cited by 182
Jahrling, P. B., Geisbert, J., Swearengen, J. R., Jaax, G. P., Lewis, T., Huggins, J. W., Schmidt, J. J., LeDuc, J. W., & Peters, C. J. (1996) · Imported Virus Infections · doi:10.1007/978-3-7091-7482-1_12 · Cited by 175
Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic Fever
Hensley, L. E., Stevens, E. L., Yan, S.-C. B., Geisbert, J. B., Macias, W. L., Larsen, T., Daddario-DiCaprio, K. M., Cassell, G. H., Jahrling, P. B., & Geisbert, T. W. (2007) · The Journal of Infectious Diseases · doi:10.1086/520598 · Cited by 157
Gupta, M., Mahanty, S., Bray, M., Ahmed, R., & Rollin, P. E. (2001) · Journal of Virology · doi:10.1128/jvi.75.10.4649-4654.2001 · Cited by 147
Geisbert, T. W., Daddario-DiCaprio, K. M., Geisbert, J. B., Young, H. A., Formenty, P. B. H., Fritz, E. A., Larsen, T., & Hensley, L. E. (2007) · The Journal of Infectious Diseases · doi:10.1086/520608 · Cited by 141
Ebola Hemorrhagic Fever: Evaluation of Passive Immunotherapy in Nonhuman Primates
Jahrling, P. B., Geisbert, J. B., Swearengen, J. R., Larsen, T., & Geisbert, T. W. (2007) · The Journal of Infectious Diseases · doi:10.1086/520587 · Cited by 129
A shared structural solution for neutralizing ebolaviruses
Dias, J. M., Kuehne, A. I., Abelson, D. M., Bale, S., Wong, A. C., Halfmann, P., Muhammad, M. A., Fusco, M. L., Zak, S. E., Kang, E. H., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2150 · Cited by 116
Self-citationPostexposure Treatment of Marburg Virus Infection
Geisbert, T. W., Hensley, L. E., Geisbert, J. B., Leung, A., Johnson, J. C., Grolla, A., & Feldmann, H. (2010) · Emerging infectious diseases · doi:10.3201/eid1607.100159 · Cited by 93
The Marburg Virus Outbreak of 1967 and Subsequent Episodes
Slenczka, W. (1999) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-59949-1_4 · Cited by 89
Ebola haemorrhagic fever in Zaire, 1995
Clegg, J. C. S., & Lloyd, G. (1995) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-199508000-00001 · Cited by 77
Clarification and guidance on the proper usage of virus and virus species names
Kuhn, J. H., & Jahrling, P. B. (2010) · Archives of Virology · doi:10.1007/s00705-010-0600-9 · Cited by 43
Cited by
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J. B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., et al. (2014) · Nature · doi:10.1038/nature13777 · Cited by 987
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
Warren, T. K., Wells, J., Panchal, R. G., Stuthman, K. S., Garza, N. L., Van Tongeren, S. A., Dong, L., Retterer, C. J., Eaton, B. P., Pegoraro, G., et al. (2014) · Nature · doi:10.1038/nature13027 · Cited by 610
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea
van Griensven, J., Edwards, T., de Lamballerie, X., Semple, M. G., Gallian, P., Baize, S., Horby, P. W., Raoul, H., Magassouba, N., Antierens, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1511812 · Cited by 536
Olinger, G. G., Pettitt, J., Kim, D., Working, C., Bohorov, O., Bratcher, B., Hiatt, E., Hume, S. D., Johnson, A. K., Morton, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213709109 · Cited by 366
Milligan, I. D., Gibani, M. M., Sewell, R., Clutterbuck, E. A., Campbell, D., Plested, E., Nuthall, E., Voysey, M., Silva-Reyes, L., McElrath, M. J., et al. (2016) · JAMA · doi:10.1001/jama.2016.4218 · Cited by 324
Metadata
- Authors
- Dye, J. M., Herbert, A. S., Kuehne, A. I., Barth, J. F., Muhammad, M. A., Zak, S. E., Ortiz, R. A., Prugar, L. I., & Pratt, W. D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-03-12
- Volume
- 109
- Issue
- 13
- Pages
- 5034-5039
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2028463307
- Cited by
- 268
- References
- 25
- FWCI
- 22.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.